This CME program is derived from content presented at the 2024 Eastern Pulmonary Conference. The expert faculty, Dr. Nicola Hanania, will first review newer maintenance therapies for chronic obstructive pulmonary disease (COPD). Following, he will analyze clinical trial data for new and emerging COPD treatments, including long-acting muscarinic antagonist (LAMA) therapeutics. Lastly, Dr. Hanania will review barriers to care and the unmet needs for patients with COPD and discuss the importance of patient education to improve treatment adherence.
Pulmonologists and other healthcare professionals involved in the treatment and management of patients with COPD
Review newer maintenance therapies for COPD
Analyze clinical trial data for new and emerging COPD treatments including long-acting muscarinic antagonist (LAMA) therapeutics
Recognize barriers to care and unmet needs for patients with COPD and engage in patient education to improve treatment adherence
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
Faculty | Relationship Identified With: |
Nicola A. Hanania, MD | Consultant/Advisor: AstraZeneca; Amgen; Chiesi; Genentech, Inc.; GSK; Regeneron; Sanofi
Grant/Research Support: AstraZeneca; Chiesi; Genentech, Inc.; GSK; Regeneron; Sanofi |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC and Chelsey Simonds hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Mylan Specialty L.P., a Viatris Company.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Mylan Specialty L.P., a Viatris Company do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.